阿托伐他汀钙片联合贝那普利片治疗高血压肾病的临床研究  

Clinical trial of atorvastatin calcium tablets combined with benazepril tablets in the treatment of hypertension nephropathy

作　　者：王学敏[1] 王婧[1] 赵讯[1] 王向托[1] 赵宝青 戴鹏[2] WANG Xue - min;WANG Jing;ZHAO xun;WANG Xiang -Tuo;ZHAO Bao- qing;DAI Peng(Department of Nephrology , Harrison International Peace Hospital, Hengshui 053000, Hebei Province, China;Department of Electrophysiology, Jizhou District Hospital, Hengshui 053200, Hebei Province, China)

机构地区：[1]哈励逊国际和平医院肾内科,河北衡水053000 [2]冀州市医院电生理科,河北衡水053000

出　　处：《中国临床药理学杂志》2018年第11期1306-1308,共3页The Chinese Journal of Clinical Pharmacology

基　　金：衡水市科学技术研究与发展计划课题资助项目(2016014093Z)

摘　　要：目的观察阿托伐他汀钙片联合贝那普利片治疗高血压肾病的临床疗效及安全性。方法将88例高血压肾病患者随机分为对照组和试验组,每组44例。对照组予以贝那普利每次10 mg,qd,口服;试验组在对照组治疗的基础上,予以阿托伐他汀钙片每次10 mg,qd,口服。2组患者均治疗12周。比较2组患者的临床疗效、肾损伤及内皮损伤指标,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为93.18%(41例/44例)和75.00%(33例/44例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的尿素氮分别为(5.31±0.66)和(7.03±0.72)mmol·L^(-1),血清肌酸酐分别为(100.75±12.61)和(117.65±13.42)μmol·L^(-1),β2微球蛋白分别为(1.92±0.19)和(2.62±0.39)mg·L^(-1),胱抑素C分别为(0.99±0.14)和(1.44±0.20)mg·L^(-1),内皮素分别为(194.47±23.41)和(284.68±31.11)ng·L^(-1),差异均有统计学意义(均P<0.05)。2组患者的药物不良反应均以头痛和胃肠道反应为主,试验组和对照组的总药物不良反应发生率分别为15.91%和6.82%,差异无统计学意义(P>0.05)。结论贝那普利片联合阿托伐他汀钙片治疗高血压肾病的临床疗效确切,其能显著改善患者的肾损伤和内皮损伤,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of atorvastatin calcium tablets combined with benazepril tablets in the treatment of hypertension nephropathy. Methods A total of 88 patients with hypertension nephropathy were randomly divided into control and treatment groups with 44 cases per group. Control group was treated with benapril 10 mg per time,qd,orally. Treatment group was treated with atorvastatin calcium tablets 10 mg per time,qd,orally,on the basis of control group. Two groups were treated for 12 weeks. The clinical efficacy,indexes of renal injury and endothelial injury,and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were 93. 18%（ 41 cases/44 cases） and 75. 00%（ 33 cases/44 cases） with significant difference（ P〈0. 05）. After treatment,the main indexes of treatment and control groups were compared： urea nitrogen were（ 5. 31 ± 0. 66）and（ 7. 03 ± 0. 72） mmol · L^（-1）,serum creatinine were（ 100. 75 ± 12. 61）and（ 117. 65 ± 13. 42） μmol· L^（-1）,β2 microglobulin were（ 1. 92 ± 0. 19） and（ 2. 62 ± 0. 39） mg · L^（-1）,cystatin C were（ 0. 99 ± 0. 14） and（ 1. 44 ± 0. 20） mg · L^（-1）,endothelin were（ 194. 47 ± 23. 41） and（ 284. 68 ± 31. 11）ng·L^（-1）,the differences were statistically significant（ all P〈0. 05）. The adverse drug reactions of two groups were headache and gastrointestinal reaction. The total incidences of treatment and control groups were 15. 91% and 6. 82%without significant difference（ P〉0. 05）. Conclusion Atorvastatin calcium tablets combined with benazepril tablets have a definitively clinical efficacy in the treatment of hypertension nephropathy,which can improve the renal injury and endothelial injury,without increasing the incidence of adverse drug reactions.

关 键 词：阿托伐他汀钙片 贝那普利片 高血压肾病 安全性 

分 类 号：R972[医药卫生—药品]